Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors

BACKGROUND: Several mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated NSCLC have been described including the T790M mutation and MET amplification. Whereas T790M mutation confers prolonged survival and sensitivity to 3rd generation TKIs, data are lacking on...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldacci, Simon, Mazieres, Julien, Tomasini, Pascale, Girard, Nicolas, Guisier, Florian, Audigier-Valette, Clarisse, Monnet, Isabelle, Wislez, Marie, Pérol, Maurice, Dô, Pascal, Dansin, Eric, Leduc, Charlotte, Giroux Leprieur, Etienne, Moro-Sibilot, Denis, Tulasne, David, Kherrouche, Zoulika, Labreuche, Julien, Cortot, Alexis B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739624/
https://www.ncbi.nlm.nih.gov/pubmed/29285237
http://dx.doi.org/10.18632/oncotarget.21707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739624/
https://www.ncbi.nlm.nih.gov/pubmed/29285237
http://dx.doi.org/10.18632/oncotarget.21707

Ejemplares similares